For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Omiganan is a synthetic 12-amino acid cationic peptide derived from indolicidin, an antimicrobial peptide from bovine neutrophil granules. It shares the cathelicidin protein family with the human peptide LL-37 (profiled separately), but its direct structural parent is the bovine indolicidin, not LL-37. Omiganan has the broadest clinical trial record of any synthetic antimicrobial peptide: Phase 3 for catheter infection prevention (missed primary endpoint) and papulopustular rosacea (statistically significant vs. vehicle), Phase 2 for acne vulgaris (positive), atopic dermatitis (microbiome recovery without clinical improvement), seborrheic dermatitis (negative vs. placebo), and HPV-induced anogenital lesions (96.6% HPV viral load reduction in anogenital warts, p=0.045). No indication has achieved regulatory approval.
Important nomenclature correction: Omiganan is often described as an 'LL-37 analog' in community contexts because both are cathelicidins -- but this framing is misleading. Omiganan's direct structural parent is indolicidin, a 13-amino acid cathelicidin isolated from bovine neutrophil granules. LL-37 is the sole human cathelicidin and is a distinct 37-amino acid peptide. Both belong to the same protein superfamily (cathelicidins), but they share only family-level homology, not direct structural derivation. Omiganan's 12-amino acid sequence (ILRWPWWPWRRK-amide) is a modified version of indolicidin, not a truncation or modification of LL-37. This profile covers omiganan; LL-37 itself is profiled separately (profile #29 in this database).
Omiganan is the most clinically advanced synthetic antimicrobial peptide by number of completed trials. It has been tested across six distinct indications across more than a decade of clinical development (roughly 2000 to present). The pattern of results is instructive: in vitro and preclinical activity has been impressive and broad-spectrum; clinical translation has been inconsistent and indication-dependent. This gap between bench and bedside is the defining story of antimicrobial peptide drug development broadly.
The Phase 3 catheter infection trial (NCT00231153) is the critical negative result in the omiganan record. In a large randomized trial using a rigorous comparator (povidone-iodine), omiganan 1% gel failed to demonstrate superiority on the primary endpoint (catheter-related bloodstream infections). It did achieve secondary endpoints: 21% reduction in catheter colonization and 50% reduction in tunnel infections. The FDA requires superiority on pre-specified primary endpoints, not just secondary signals -- so this trial, despite showing some antimicrobial activity, was insufficient for approval.
The 2023 seborrheic dermatitis randomized trial specifically compared omiganan 1.75% to both ketoconazole and placebo; omiganan did not improve any clinical endpoint vs. placebo while ketoconazole clearly outperformed both. This result directly contradicted the expected antimicrobial/antifungal mechanism.
Indolicidin, omiganan's parent compound, was isolated from the cytoplasmic granules of bovine neutrophils in the early 1990s. It is a 13-amino acid, tryptophan-rich cathelicidin with broad-spectrum antimicrobial activity and a distinctive mechanism involving cytoplasmic membrane disruption followed by entry into the cell and inhibition of DNA, RNA, and protein synthesis. Indolicidin's clinical development was hampered by hemolytic toxicity at effective concentrations.
Omiganan (formerly MBI 226, later CLS001) was synthesized by Migenix Inc. (formerly Micrologix Biotech, Vancouver, Canada) as a synthetic analog of indolicidin with 12 residues and modifications intended to reduce hemolytic toxicity while preserving antimicrobial potency. The modifications included C-terminal amidation and sequence optimization. The resulting compound retained indolicidin's broad-spectrum activity with a markedly improved safety profile for topical use, with no detectable systemic absorption at clinical concentrations.
The development pathway spanned multiple licensing arrangements. For the catheter indication, Migenix retained development rights and ran its own Phase 3 trial. For dermatological indications, Cutanea Life Sciences licensed worldwide dermatological rights and ran the rosacea and acne programs under the CLS001 designation. The dermatological program was eventually acquired and continued by Creabilis (later acquired by Timber Pharma), running the Phase 3 rosacea program. The HPV, atopic dermatitis, and seborrheic dermatitis studies were run by Dutch academic groups (primarily from Leiden University Medical Center).
The cathelicidin connection to LL-37 is mechanistically relevant even if the structural derivation is different. LL-37 and omiganan share the broad cathelicidin family properties: cationic charge, amphipathic helical structure in membrane environments, membrane-disrupting antimicrobial activity, and immunomodulatory properties including cytokine modulation and anti-inflammatory effects. Rosacea skin is characterized by dysregulated cathelicidin signaling -- LL-37 is elevated and abnormally processed in rosacea patients -- which provided the mechanistic rationale for testing omiganan in this context.
Omiganan is a cationic antimicrobial peptide (AMP) that kills microorganisms through membrane disruption and intracellular target interference. The cationic charge (from multiple arginine and lysine residues) drives electrostatic attraction to the negatively charged phospholipid membranes of bacteria and fungi. Once at the membrane surface, omiganan inserts into the lipid bilayer, driven by its hydrophobic tryptophan-rich core, disrupting membrane integrity and causing depolarization and loss of intracellular contents.
Unlike conventional antibiotics that target specific biosynthetic enzymes or ribosomal subunits, omiganan's mechanism is physical disruption of membranes. This non-specific mechanism underlies its broad-spectrum activity (gram-positive bacteria, gram-negative bacteria, fungi) and the theoretical low resistance potential -- organisms cannot easily mutate a single protein target to avoid membrane disruption. Omiganan also inhibits macromolecular synthesis (DNA, RNA, and protein) at the cellular level, adding a second mechanism of action beyond membrane disruption.
The anti-inflammatory and immunomodulatory properties relevant to rosacea and atopic dermatitis are distinct from the antimicrobial mechanism. Cationic peptides including omiganan can: bind and neutralize lipopolysaccharide (LPS) and lipoteichoic acid (LTA), proinflammatory bacterial cell wall components, thereby reducing TLR4- and TLR2-mediated cytokine release; inhibit secretion of proinflammatory cytokines (TNF-alpha, IL-1) from host cells even in the absence of bacteria; and modulate the host innate immune response in ways that reduce inflammation independently of direct antimicrobial killing.
In rosacea, the cathelicidin LL-37 is overexpressed and abnormally processed into fragments that drive chronic vascular and inflammatory responses. The hypothesis for omiganan's use in rosacea is that exogenous cathelicidin-like peptides (such as omiganan) can modulate this dysregulated signaling: competing for receptor occupancy, neutralizing inflammatory triggers, and reducing the proinflammatory cascade triggered by abnormal LL-37 fragment accumulation. The Phase 3 rosacea data supports this hypothesis; the seborrheic dermatitis negative result suggests the mechanism is condition-specific.
Antiviral activity against HPV: omiganan reduced HPV DNA load by 96.6% in anogenital warts patients in the Phase 2 trial (Rijsbergen et al., 2020). The proposed mechanism involves direct virucidal activity through membrane disruption of the viral envelope (though HPV is a non-enveloped virus -- the mechanism likely involves disruption of virion capsid integrity and reduction of viral DNA replication in infected keratinocytes, though the precise virucidal mechanism is not fully characterized).
Phase 2 (n=240): Among the once-daily treatment arms, a clear dose-dependent response was observed. Patients receiving omiganan 2.5% once daily showed a mean 31% reduction in inflammatory facial lesions vs. a 14% reduction in once-daily vehicle at week 9. In the prespecified subgroup with 18 or more lesions at baseline (severe rosacea), omiganan 2.5% once daily showed a mean 40% reduction vs. an 11% increase in the vehicle group -- a meaningful and clinically relevant difference. Twice-daily application did not improve over once-daily, establishing the once-daily regimen for Phase 3.
Phase 3 (n=approximately 450): Omiganan 1.6% gel was statistically significantly superior to vehicle in both co-primary endpoints at week 12: mean inflammatory lesion count reduction was 18.1 vs. 13.5 lesions for vehicle (p=0.043); the proportion of subjects achieving at least 2 IGA grades improvement was 26.3% vs. 16.9% for vehicle (p=0.019). The compound was well tolerated with similar adverse event rates between omiganan and vehicle groups. No serious adverse events were reported.
The Phase 3 result establishes that omiganan 1.6% gel is superior to vehicle for papulopustular rosacea. However, results information for the referenced applicable clinical trials was not submitted to ClinicalTrials.gov per an FDA letter to Migenix in 2022, and no NDA has been filed. The reasons for non-submission and non-filing are commercial rather than safety-based, and the clinical data showing efficacy vs. vehicle remains valid. Comparisons to currently approved rosacea therapies (ivermectin 1% cream, metronidazole) have not been conducted.
The rosacea data represents the strongest efficacy signal in the omiganan clinical record. Phase 3 superiority over vehicle for both lesion count and IGA was demonstrated in a large adequately powered trial. The absence of FDA approval reflects commercial development decisions and the requirement for regulatory submission, not failure of efficacy. The absolute magnitude of effect (18.1 vs. 13.5 lesions at week 12) should be evaluated relative to the clinically meaningful threshold for rosacea treatment.
The Phase 3 catheter trial is the critical negative result in the omiganan clinical record. The trial tested omiganan 1% gel vs. povidone-iodine for prevention of catheter-related bloodstream infections (primary endpoint) and catheter colonization (key secondary endpoint).
The primary endpoint (catheter-related bloodstream infection rates) was not significantly different between omiganan and povidone-iodine. This was the definitive endpoint for regulatory approval and the trial failed to demonstrate superiority.
Secondary endpoints showed some benefit: omiganan achieved a 21% reduction in catheter colonization and a 50% reduction in tunnel infections compared to povidone-iodine. These secondary signals are clinically meaningful but insufficient for FDA approval, which requires the primary endpoint to be met. The FDA does not accept secondary endpoints as the basis for approval when a pre-specified primary endpoint fails.
The gap between the colonization benefit and the bloodstream infection benefit likely reflects the established observation that catheter colonization is a necessary but not sufficient step in the pathway to bloodstream infection -- most colonized catheters do not progress to bloodstream infection. The antimicrobial activity of omiganan reduced colonization successfully but the resulting reduction in downstream bloodstream infections did not reach statistical significance, possibly due to trial size, patient population heterogeneity, or the baseline low rate of bloodstream infections achievable with standard povidone-iodine care.
A 2019 review noted that omiganan 'did achieve significance in other endpoints (reducing catheter colonisation), allowing it to progress into confirmatory 3b trials' -- but these confirmatory trials did not alter the primary endpoint outcome. The catheter indication is considered closed as a development pathway for omiganan.
The catheter Phase 3 is a clear negative result on the primary endpoint and should be reported as such. The secondary endpoint signal (colonization reduction) shows the antimicrobial mechanism works in vivo but does not translate to clinically meaningful primary infection prevention at the level required for regulatory approval. This is the most important failed trial in the omiganan record.
Anogenital warts (n=24): Omiganan 2.5% gel produced a statistically significant reduction in HPV viral load compared to placebo. The HPV load decreased by 96.6% (95% confidence interval -99.9 to -7.4%, p=0.045) in the omiganan group while the placebo group initially showed an increase in viral load. Treatment adherence was 99%. No serious adverse events occurred; all 27 adverse events were mild, transient, and self-limiting.
Vulvar HSIL (n=12): HPV load remained stable in both groups and no statistically significant difference was found between omiganan and placebo. Both pain and itch showed high inter-patient variability with no significant differences between groups (p=0.81 for pain; p=0.66 for itch).
The pattern is notable: omiganan reduced HPV viral load in externally accessible anogenital warts but not in vulvar HSIL lesions. This distinction may reflect pharmacokinetic differences -- external anogenital warts are more accessible to topical penetration than the keratinized skin of vulvar HSIL -- or biological differences in the viral compartment. The 96.6% HPV load reduction in anogenital warts is a large pharmacodynamic effect for a topical agent.
A subsequent systematic review and meta-analysis (published 2025) concluded that omiganan was ineffective for usual-type VIN (high-risk HPV lesions) despite adherence to treatment, consistent with the null result in vulvar HSIL.
The antiviral activity of omiganan in anogenital warts (96.6% HPV load reduction, p=0.045) is the most intriguing finding in the omiganan portfolio outside of rosacea. The sample size (n=24) is too small to draw definitive efficacy conclusions, and clinical lesion outcomes (lesion count, size) were not significantly different despite the viral load reduction. This requires a larger Phase 2 or Phase 3 trial specifically powered for clinical endpoints to determine whether the viral load reduction translates to clinical benefit.
Atopic dermatitis (2022, JAAD): Omiganan recovered cutaneous dysbiosis -- the skin microbiome showed improvement toward healthier composition -- without producing statistically significant clinical improvement. SCORAD scores and body surface area measures did not differ significantly between omiganan and vehicle. The microbiome finding is pharmacodynamically interesting (omiganan reaches and modifies the skin microbial community) but the dissociation from clinical outcomes means it cannot support efficacy claims.
Seborrheic dermatitis (2023, n=37): Omiganan 1.75% did not result in significant clinical improvement vs. placebo on any endpoint: SDASI score difference -1.5 (CI -3.6 to 0.5, p=0.1429); IGA difference -0.3 (CI -0.7 to 0.1, p=0.0971); BSA difference -0.11 (CI -0.47 to 0.24, p=0.5220). Importantly, ketoconazole 2% was significantly superior to placebo on all three endpoints. Omiganan also did not affect Malassezia or Staphylococcus abundances in the skin microbiome -- the expected antimicrobial targets in seborrheic dermatitis. The authors concluded that previously established antimicrobial and antifungal properties 'could not be demonstrated' in this trial.
These two results together establish a pattern: omiganan can affect skin microbial communities (shown in atopic dermatitis) but does not reliably demonstrate the clinical antimicrobial and antifungal effects seen in vitro and in preclinical models. The seborrheic dermatitis null result against Malassezia specifically -- a key target organism -- is a significant finding that limits the antimicrobial rationale for skin conditions where fungal targets dominate.
The atopic dermatitis and seborrheic dermatitis results collectively establish an important limitation: topical omiganan's in vitro antimicrobial activity does not consistently translate to clinical skin disease improvement. The microbiome recovery without clinical improvement in atopic dermatitis, and the flat performance vs. placebo in seborrheic dermatitis (where ketoconazole clearly worked), suggest that skin penetration, local bioavailability, or pathogen complexity in clinical conditions limits the therapeutic effect relative to what bench data predicts.
In the Phase 2a acne study (n=75, 6 weeks), omiganan reduced inflammatory lesions (papules and pustules) by 39% vs. 21% in the placebo group. For non-inflammatory lesions (comedones), the results were reversed: omiganan showed 10% reduction vs. 25% reduction in the placebo group -- meaning comedones responded better to placebo (possibly reflecting natural fluctuation). Physician's Global Severity Assessment scores improved more in the omiganan group.
The inflammatory lesion reduction signal (39% vs. 21%) aligns with omiganan's dual antimicrobial and anti-inflammatory mechanism -- Propionibacterium acnes (now Cutibacterium acnes) is the primary bacterial driver of inflammatory acne, and omiganan has demonstrated in vitro activity against it. The anti-inflammatory cytokine modulation properties provide a second mechanism for acne improvement beyond direct bactericidal activity.
The Japanese pharmaceutical company Maruho has licensed rights for acne indications in Japan and conducted additional Phase 2 trials for moderate to severe acne vulgaris. Results from the Maruho Japanese trials have not been fully published in the peer-reviewed literature as of 2026.
The Phase 2a acne result is a positive signal supporting continued development for inflammatory acne. The 39% vs. 21% inflammatory lesion reduction is clinically meaningful. This was a single Phase 2a study (n=75, 6 weeks) and would require a Phase 3 program for regulatory submission. Development in the USA/EU for acne has not proceeded beyond Phase 2; development in Japan through Maruho is ongoing.
Omiganan is a topical-only compound; dose is expressed as gel concentration (% w/w) rather than milligrams or micrograms per dose. All clinical trials have used topical gel formulations with concentrations from 1% to 2.5%. Not FDA-approved; not commercially available for prescription use as of 2026. No compounding pharmacy availability documented. Not on WADA Prohibited List. Research groups can obtain omiganan through chemical suppliers for preclinical research. The most clinically relevant completed protocols are: rosacea (1.6%, once daily, 12 weeks) and anogenital warts (2.5%, once daily, 12 weeks). Seborrheic dermatitis (1.75%, twice daily, 4 weeks) showed no clinical benefit. The catheter protocol (1% gel at insertion and dressing changes) should be considered inactive based on Phase 3 primary endpoint failure.
Omiganan is the most clinically advanced synthetic antimicrobial peptide by trial count. Its closest database comparator is LL-37 (profile #29), which shares the cathelicidin family membership but is structurally distinct (human-derived, 37 amino acids vs. omiganan's 12 amino acids from bovine indolicidin). Both have anti-inflammatory and immunomodulatory properties in addition to direct antimicrobial activity. In the skin indication space, omiganan competes pharmacologically with approved topical treatments: metronidazole 0.75% and 1%, ivermectin 1%, and azelaic acid for rosacea; retinoids, benzoyl peroxide, and clindamycin for acne. Unlike these small-molecule topicals, omiganan's membrane-disruption mechanism is theoretically resistance-proof. In the antimicrobial resistance context, omiganan's activity against MRSA (MIC 50/90: 16 mg/L), ESBL-producing E. coli, and vancomycin-resistant enterococci -- unaffected by resistance phenotype -- positions it differently from conventional antibiotics. No other compound in this database has omiganan's combination of antimicrobial, antifungal, and antiviral mechanisms in a single topical agent.
Omiganan has an excellent safety profile across all published human trials. The most consistent finding across all Phase 2 and Phase 3 studies is well-tolerance with minimal adverse events.
Local tolerability: application site reactions (mild irritation, redness, or discomfort) are the most commonly reported events and occur at rates similar to placebo in most studies. In the catheter study, local skin irritation rates were acceptable. In the rosacea Phase 3, adverse event incidence was similar between omiganan and vehicle groups. In the HPV trial (n=36 total), 27 adverse events were reported across both groups, all mild, transient, and self-limiting with no serious adverse events.
Systemic absorption: A key safety advantage of omiganan is non-detectable systemic absorption at clinical topical concentrations (1% to 2.5%). This means the documented systemic toxicities of cationic antimicrobial peptides at injectable doses (nephrotoxicity, hemolysis) are not relevant to topical omiganan use at therapeutic concentrations. This pharmacokinetic profile was verified in Phase 1 human studies.
Resistance potential: The membrane-disruption mechanism is theoretically resistance-resistant -- bacteria cannot easily mutate to avoid cationic membrane disruption without losing membrane integrity themselves. No emergence of omiganan resistance in clinical use has been documented. This is clinically important in the context of antimicrobial stewardship, though omiganan has not reached broad enough use for this to be tested at population scale.
Microbiome effects: The atopic dermatitis Phase 2 study (Niemeyer-van der Kolk et al., 2022, JAAD) showed omiganan recovered cutaneous dysbiosis (changed the skin microbiome toward a more diverse, healthier composition) without producing clinical improvement. The seborrheic dermatitis study showed no effect on Malassezia or Staphylococcus abundances, contrasting with the in vitro antimicrobial activity. These findings raise questions about whether topical omiganan achieves sufficient antimicrobial concentrations in clinical skin conditions to meaningfully alter the microbiome in all contexts.
Omiganan's clinical story is the clearest demonstration in this database of the gap between antimicrobial peptide bench performance and clinical translation. In vitro, omiganan kills gram-positive bacteria, gram-negative bacteria, and fungi with a potency and breadth that has made it a standard comparator in antimicrobial peptide research for two decades. In clinical trials, it has produced positive signals in some settings and failed in others.
The positive results are real: the rosacea Phase 3 showed statistically significant superiority over vehicle on pre-specified endpoints; the Phase 2a acne showed a meaningful inflammatory lesion reduction signal; the anogenital wart HPV trial showed a 96.6% viral load reduction. These are not artifacts.
The negative results are also real: the Phase 3 catheter trial failed its primary endpoint against a standard comparator; the seborrheic dermatitis trial showed no benefit vs. placebo (while ketoconazole clearly worked); the atopic dermatitis trial showed microbiome changes without clinical improvement. These failures are not random noise -- they suggest that the conditions under which omiganan's in vitro activity translates to clinical benefit are narrower than its broad-spectrum preclinical profile implies.
The nomenclature clarification matters: this is not an LL-37 analog in the structural sense -- it derives from bovine indolicidin. The shared cathelicidin family membership provides mechanistic rationale for its use in cathelicidin-driven skin conditions like rosacea, but practitioners should not assume that omiganan data predicts LL-37 outcomes or vice versa.
The absence of FDA approval despite multiple Phase 3 trials reflects both development pipeline decisions and the regulatory reality that positive vs. vehicle results still require head-to-head non-inferiority or superiority vs. approved comparators to achieve a meaningful market position in competitive dermatology. The rosacea program's efficacy data is intact; the commercial pathway was not pursued.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use